TVS Motor Company launches its revolutionary premium electric crossover, TVS X; sets new global benchmarks in the EV industry
24.8.2023 13:38:00 EEST | Business Wire | Press release
In line with its commitment towards offering sustainable mobility solutions globally, TVS Motor Company, a reputed manufacturer of two and three-wheelers, today launched the keenly anticipated, TVS X its flagship crossover EV with a host of industry first attributes. This revolutionary machine sets a new benchmark in the global electric mobility industry with its stunning design, unmatched performance, and cutting-edge tech features, carving out a new category in the electric mobility segment. As a frontrunner in sustainable mobility solutions, TVS Motor Company aims to transform the EV segment and reaffirm its commitment to a more sustainable and cleaner future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230824401679/en/
Mr. Sudarshan Venu, MD, TVS Motor Company at the launch of TVS X in Dubai (Photo: Business Wire)
With a rapid uptick in the adoption of EVs globally, the TVS X will play a pivotal role in creating a niche in the EV industry. Backed by rider-first engineering, to deliver rider-machine unity, this lean-mean-clean machine designed to create desire, has been developed from the ground up at TVS Motor’s R&D facility. Designed, developed, and made-in-India, TVS X comes with a powerful electric motor and advanced battery technology. This machine promises not only thrilling acceleration but also an impressive range, ensuring convenience and comfort, thus making it an ideal zero-emission and sophisticated electric mobility solution. This flagship EV from the house of TVS Motor introduces not only stellar performance, but also an array of safety features, with a number of class leading offerings in line with its vision of creating a clean, intuitive and tech-first product. It is designed for young Indians who are the global trendsetters.
Speaking at the launch, Mr. Sudarshan Venu, Managing Director, TVS Motor Company said, “Our dedication to harness technology and innovation towards a greener and more sustainable future has brought to us this incredibly desirable machine. This launch marks a defining moment in TVS Motors’ journey of showcasing a made-in-India EV, the TVS X. It has been designed for the global citizens, who are trendsetters and visionaries with a passion for technology. It is set to inspire a shift towards premium yet sustainable and technologically advanced mobility solutions. It leads the way to become a global benchmark for a machine that is born electric. The TVS X embodies innovation with a disruptive mindset. It has sustainability at its core and embodies the next era of clean mobility. With its remarkable performance, premium aesthetics, and integrated, intuitive, and personalised experiences, we believe it will redefine mobility worldwide.”
Booking for TVS X are open now on our website https://www.tvsmotor.com/electric-vehicle/tvs-x. Deliveries across 15 cities will start from Nov 2023 in a phase-wise manner.
TVS X will be available at a Thrill-electric introductory price of INR. 2,49,990/- (Ex-showroom Bengaluru) with portable 950W chargers at INR. 16,275 (including GST) and a 3kW Smart X Home rapid charger is also available as an option. FAME incentive is not applicable for TVS X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230824401679/en/
Contact information
For more information, please contact:
KS Harini – ks.harini@tvsmotor.com
Nikita Verma – nikita.verma@tvsmotor.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom